This preview shows page 1. Sign up to view the full content.
Unformatted text preview: course of a phase I trial (O’Quigley et al., 1990; Whitehead, 1997). Consequently, the phase I target dose is usually deﬁned in terms of the prevalence of treatment side eﬀects without direct regard for treatment eﬃcacy. For the majority of cytotoxic agents, toxicity is considered a prerequisite for optimal antitumor activity (Wooley and Schein, 1979) and the probability of treatment beneﬁt is assumed to monotonically increase with dose, at least over the range of doses under consideration in the phase I trial. Consequently, the MTD of a cytotoxic agent typically corresponds to the highest dose associated with a tolerable level of Copyright n 2004 by Marcel Dekker, Inc. All Rights Reserved....
View Full Document
This note was uploaded on 06/13/2011 for the course PHYSICS 101 taught by Professor Shu during the Spring '11 term at FIU.
- Spring '11